Global Osteoporosis Drugs Market
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) — The “Global Osteoporosis Drugs Market Report by Route of Administration Product Type Countries and Company Analysis, 2024-2032” report has been added to ResearchAndMarkets.com’s offering.
The osteoporosis drugs market is expected to over US$ 25.53 billion by 2032 from US$ 17.43 billion by 2023, with a CAGR growth of 4.33% from 2024 to 2032 because of the rising incidence of osteoporosis, new drugs, and enhanced awareness of bone health.
There is growing consumer interest in the prevention and cure of osteoporosis due to the global aging of the population. Senior citizens particularly women are at a higher risk of developing osteoporosis since bones progressively become thinner and weaker with age, thus the risk of fractures. Thus, demographic changes and ageing affect the occurrence of osteoporosis associated ailments; healthcare improvements must be made to respond to these conditions.
Treatment strategies such as bisphosphonates, selective estrogen receptor modulators and monoclonal antibodies are necessary to correct low bone density and reduce fracture risks. The unprecedented aging population that demands efficient treatment options for osteoporosis creates more pressure on Pharma to develop niche medicines to boost overall bone strength and decrease the occurrence of painful fractures.
Increased awareness about osteoporosis and its importance
Growing awareness about osteoporosis and the value of bone health contributes greatly and leads to the rise of osteoporosis drug market. Precariousness of osteoporosis is raised by public health activities and other awareness raising projects on the benefits of timely diagnosis and treatment; as a result, people become more concerned about their health.
This awareness fosters those individuals and groups mostly affected like the postmenopausal women and older individuals to seek medical help and get tested for bone density scans. This means that through early diagnosis the condition is first managed with proper osteoporosis drugs, and severe outcomes such as fractures are prevented. Therefore, osteoporosis medications are on demand because the market is improving its efforts of aiming for prevention of the situation that is affecting a large number of people.
Advancements in Drug Development:
Technological advancements in the drug formulation as well as in the ways that drug is released into the system boosts the therapeutic outcomes as well as patient adherence, thus offsetting feelings of market saturation for osteoporosis medicines. complexations guarantee better adsorption and prolonged releasing of the medication, which positively affects the therapeutic efficacy.
Story continues
New drugs like oral medication with lesser side effects, new injectable preparations with longer intervals between doses, operation of trans dermal patch, nasal sprays have greater patient compliance as they are easily acceptable by the patient. These improvements cut down the woes concerning frequent dosing and also strive to boost up the results of patients’ well-being.
Asia Pacific Osteoporosis Drugs Market
The osteoporosis drugs market in the Asia Pacific region is expected to grow rapidly in the upcoming years. The population is aging in the developed countries of Asia, mostly in Japan and South Korea and their needs for frailty treatment owing to osteoporosis and fractures are vast. Increase in geriatric population, perfected healthcare spending, the availability of advanced healthcare services, and diagnostics support the market growth.
Therefore, the objective of governments to raise awareness and encourage timely diagnosis of osteoporosis is significant in organizational development of the market. Also, through research and development of new drugs and partnerships between international and local health companies, the options for osteoporosis medication have improved in the Asia Pacific. The market access of osteoporosis drug is trending and there is a tremendous potential for the pharma companies to manage the healthcare requirements of aging demography in this segmented and transformed region.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 230 |
| Forecast Period | 2023 – 2032 |
| Estimated Market Value (USD) in 2023 | $17.43 Billion |
| Forecasted Market Value (USD) by 2032 | $25.53 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
Key Players Analysis: Overview, Recent Development & Strategies, Product Portfolio, Financial Insights
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Osteoporosis Drugs Market
6. Market Share
6.1 Market Breakup by Product Type
6.2 Market Breakup by Route of Administration
6.3 Country
7. Product Type
7.1 Bisphosphonates
7.2 Calcitonin
7.3 Rank Ligand Inhibitor
7.4 Parathyroid Hormone Therapy (PTH)
7.5 Selective Estrogen Receptor Modulators (SERMs)
7.6 Sclerostin Inhibitor
7.7 Others
8. Route of Administration
8.1 Oral
8.2 Injectable
8.3 Others
9. Country
9.1 North America
9.1.1 United States
9.1.2 Canada
9.2 Europe
9.2.1 France
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 United Kingdom
9.2.6 Belgium
9.2.7 Netherlands
9.2.8 Turkey
9.3 Asia Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 South Korea
9.3.6 Thailand
9.3.7 Malaysia
9.3.8 Indonesia
9.3.9 New Zealand
9.4 Latin America
9.4.1 Brazil
9.4.2 Mexico
9.4.3 Argentina
9.5 Middle East & Africa
9.5.1 South Africa
9.5.2 Saudi Arabia
9.5.3 UAE
10. Porter’s Five Analysis
10.1 Bargaining Power of Buyers
10.2 Bargaining Power of Suppliers
10.3 Degree of Rivalry
10.4 Threat of New Entrants
10.5 Threat of Substitutes
11. SWOT Analysis
11.1 Strength
11.2 Weakness
11.3 Opportunity
11.4 Threat
For more information about this report visit https://www.researchandmarkets.com/r/7rb3iw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
